Davita Inc vs Johnson Controls International PLC — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Johnson Controls International PLC trades at $154.56 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 8.3× Davita Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Johnson Controls International PLC for 65 Days on average.
| DVA | JCI | |
|---|---|---|
Market Cap | $11.29B | $93.28B |
Volume | 582,204 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $158.76 |
52-Week Low | $103.87 | $105.55 |
Typical Hold Time | 113 Days | 65 Days |
Enterprise Value | $24.01B | $102.12B |
Dividend Yield | — | 1.04% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
JCI trades at $155.93, down 1.78% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by 10% organic sales growth and a record $21 billion backlog. Profitability remains solid with a 14.32% net income margin and 24.42% ROE.
The stock offers upside to the $172.50 consensus price target, supported by strong fundamentals and institutional accumulation. Risks include elevated valuation multiples (P/E 43.38) and potential macroeconomic pressures on industrial demand. Continued execution on data center and building systems growth is key for sustained momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →